Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

December 10th 2024EP. 5: Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections The panelist discusses Rebyota, a treatment approved by the FDA for preventing ...

Objective: To describe emergent therapies, such as rifaximin, nitazoxanide, intravenous immunoglobulin (IVIG), tinidazole, tolevamer, and the possible use of a vaccine, in Clostridium difficile ...

The following is a summary of “Oral Capsule FMT Combined With Bezlotoxumab Is a Successful Rescue Protocol Following Failure ...

There are currently no C. difficile vaccines available, and the main treatment for the infection is a lengthy course of ...

Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA ...

The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.

a company that produces diagnostic tests for C. difficile. Petri and Tyus are also seeking a patent with UVA for alpha 2 ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...